Rafal Dziadziuszko
Dept. of Oncology and Radiotherapy, Medical University of Gdansk · Mecical University of Gdansk, Poland · Medical University of Gdansk, Gdansk, Poland
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rafal Dziadziuszko as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:52 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05718297 · Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung CancerETOP IBCSG Partners Foundation · withdrawn · NSCLC, Stage III, ALK-rearrangement · study chair
- Ph2NCT02856893 · Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)European Organisation for Research and Treatment of Cancer - EORTC · completed · NSCLC · principal investigator
- Ph2NCT02369484 · Afatinib in NSCLC With HER2 MutationETOP IBCSG Partners Foundation · completed · NSCLC · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:52 UTC. The ranking covers the 200 most relevant of 53 PubMed records, and a shared surname and initials can bring in a namesake. All 53 on PubMed
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 20172,061 citationsRCR 67.4
- Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.J Clin Oncol · 2006603 citationsRCR 13.1
- 580 citationsRCR 23.5
- Rociletinib in EGFR-mutated non-small-cell lung cancer.N Engl J Med · 2015539 citationsRCR 15.6
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.N Engl J Med · 2023529 citationsRCR 41.5
- Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2024424 citationsRCR 50.7
- 390 citationsRCR 14.0
- 264 citationsRCR 8.7
- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2024227 citationsRCR 25.8
- Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).J Thorac Oncol · 2019143 citationsRCR 4.0